CADTH Canadian Drug Expert Committee recommendation: Nitisinone (nitisinone tablets -- Cycle Pharmaceuticals Ltd.) indication : the treatment of adult and pediatric patients with hereditary tyrosinemia type 1 (HT-1) in combination with dietary restriction of tyrosine and phenylalanine
The CADTH Canadian Drug Expert Committee (CDEC) recommends that nitisinone (nitisinone tablets) be reimbursed for the treatment of adult and pediatric patients with HT-1 in combination with a dietary restriction of tyrosine and phenylalanine
Corporate Authors: | , |
---|---|
Format: | eBook |
Language: | English |
Published: |
Ottawa (ON)
Canadian Agency for Drugs and Technologies in Health
2018, August 2018
|
Edition: | Version 1.0 |
Series: | CADTH common drug review
|
Subjects: | |
Online Access: | |
Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
Summary: | The CADTH Canadian Drug Expert Committee (CDEC) recommends that nitisinone (nitisinone tablets) be reimbursed for the treatment of adult and pediatric patients with HT-1 in combination with a dietary restriction of tyrosine and phenylalanine |
---|---|
Item Description: | "Final." |
Physical Description: | 1 PDF file (8 pages) |